Spironolactone 25Mg Tablet

DRUG2 trials

Sponsors

Hamilton Health Sciences Corporation, Professor Fernando Figueira Integral Medicine Institute

Conditions

Coronary Artery CalcificationEndstage Renal DiseaseVascular Calcification

Phase 3

Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease

CompletedNCT03020303

Hamilton Health Sciences CorporationEndstage Renal Disease

Start: 2017-07-07End: 2025-03-14Updated: 2026-08-13

Prevention of the Progression of Coronary Calcification With Use of Spironolactone in Peritoneal Dialysis Patients

CompletedNCT03314493

Professor Fernando Figueira Integral Medicine InstituteCoronary Artery Calcification, Vascular Calcification

Start: 2014-11-07End: 2016-11-10Updated: 2017-10-19

Related Papers

Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial.

2025-08-0111 citations

The Aldosterone Blockade for Health Improvement Evaluation in End-Stage Renal Disease (ACHIEVE) Trial: Rationale and Clinical Research Protocol

Canadian Journal of Kidney Health and Disease2025-06-031 citations

Three week compared to seven week run-in period length and the assessment of pre-randomization adherence: A study within a trial.

2021-06-051 citations

The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward.

2019-04-0121 citations